Promising Phase 3 Results for Alzheimer's Drug Donanemab : v

In a phase 3 trial, the monoclonal antibody donanemab slowed clinical and functional decline by 35% for patients with early Alzheimer's disease. However, the drug was not without safety issues.

Related Keywords

United States , American , Mark Mintun , Joanne Pike , Eli Lilly , Percy Griffin , Maria Carrillo , Alzheimer Association , Centers For Medicare Medicaid Services , Drug Administration , Neurodegeneration Research , Alzheimer Association International Conference , Journal Of The American Medical Association , Medscape Medical , Association International Conference , American Medical , Secondary Endpoints Met , Disease Rating Scale , Clinical Dementia Rating Global Score , Medscape Medical News , Medicaid Services , Presented July , Alzheimers Disease , Lzheimer Disease , Monoclonal Antibody , Etuximab , Ituximab , Biologic Therapy , Brain , Dementia , Medicare , Mci , Mild Cognitive Impairment , Positron Emission Tomography Pet , Pet , Positron Emission Tomography , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Cognitive Impairment , A Scan Biometry , A Scan Ultrasound Biometry , Ea Scan , Amyloid Plaque ,